Overview

Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2017-04-07
Target enrollment:
0
Participant gender:
All
Summary
The study is to evaluate the percentage of patients with asthma or COPD achieving disease control
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Teva Pharmaceuticals Europe
Criteria
Inclusion Criteria:

- Patient ≥ 18 years of age who has been diagnosed with persistent asthma or patient ≥
40 years of age and/or (ex)-smoker with more than 10 pack years of smoking who has
been diagnosed with COPD

- Treatment with a stable dose (no change in dose or change by less than 50% in the last
3 months) of a Inhaled corticosteroid (ICS), Long-acting beta2-agonists (LABA), Fixed
dose combination (FDC) administered twice daily by Dry powder inhaler (DPI) for 3
months prior to enrollment in accordance with its approved indication

- Patient is willing and able to provide written informed consent;

- Patient agrees to participate in the study and to disclose any medical events to the
treating physician;

- Patient is able to complete the questionnaires.

Exclusion Criteria:

• Current enrolment or planned enrolment in an interventional study (patients are allowed
to participate in other observational or case-control studies).